Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome of chronic myelomonocytic leukemia

ABSTRACT: Transcriptome of chronic myelomonocytic leukemia

PROVIDER: PRJNA657050 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12450100_1.fastq.gz	Fastqsanger.gz
	SRR12450100_2.fastq.gz	Fastqsanger.gz
	SRR12450101_1.fastq.gz	Fastqsanger.gz
	SRR12450101_2.fastq.gz	Fastqsanger.gz
	SRR12450102_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 50

Similar Datasets

Transcriptome of chronic myelomonocytic leukemia

Project description:We report the gene expression of human chronic myelomonocytic leukemia by performing whole transcriptome shotgun sequencing of peripheral blood mononuclear cells of patients with chronic myelomonocytic leukemia.

2020-08-14 | GSE156209 | GEO

Transcriptome of ASXL1-mutant and ASXL1-wildtype chronic myelomonocytic leukemia

Project description:We report the gene expression of human chronic myelomonocytic leukemia by performing whole transcriptome shotgun sequencing of bone marrow mononuclear cells of patients with chronic myelomonocytic leukemia.

2022-02-21 | GSE159543 | GEO

Epigenome of ASXL1-mutant and ASXL1-wildtype chronic myelomonocytic leukemia

Project description:We report the chromatin characteristics of human chronic myelomonocytic leukemia by performing chromatin immunoprecipitation sequencing of histone modifications (ChIP-seq), immunoprecipitation sequencing of (hydroxy-)methylated residues (DIP-seq), and transposase accessibility sequencing (ATAC-seq) of bone marrow mononuclear cells of patients with chronic myelomonocytic leukemia.

2022-02-21 | GSE159886 | GEO

Transcriptome of ASXL1-mutant and ASXL1-wildtype chronic myelomonocytic leukemia

Project description:Transcriptome of ASXL1-mutant and ASXL1-wildtype chronic myelomonocytic leukemia

| PRJNA670006 | ENA

Methylation and chromatin abnormalities in chronic myelomonocytic leukemia.

Project description:In this study, institutional IRB approval was obtained and peripheral blood and bone marrow samples on patients with chronic myelomonocytic leukemia were collected. On the samples, we performed chromatin immuno-precipitation and next generation sequencing to assess histone modifications and epigenetic changes associated with proliferative and dysplastic phenotypes.

2020-08-18 | GSE156377 | GEO

Methylation and chromatin abnormalities in chronic myelomonocytic leukemia.

Project description:Methylation and chromatin abnormalities in chronic myelomonocytic leukemia.

| PRJNA657628 | ENA

RNA-sequencing of Chronic Myelomonocytic Leukemia and healthy donors bone marrow samples

Project description:RNA-seq of bone marrow samples of chronic myelomonocytic leukemia (CMML) patients and healthy donors to identify the molecular DNA repair pathways involved in CMML pathogenic

2020-08-07 | GSE102312 | GEO

Affymetrix SNP array data for chronic myelomonocytic leukemia samples

Project description:Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic disorder with heterogeneous clinical, morphological and genetic characteristics. Clonal cytogenetic abnormalities are found in 20-30% of patients with CMML. Patients with low risk cytogenetic features (normal karyotype and isolated loss of Y chromosome) account for approximately 80% of CMML patients and often fall into the low risk categories of CMML prognostic scores. SNP-A were performed in 82 CMML patients with low risk karyotypes and uninformative results for conventional G-banding cytogenetics (CC).

2015-12-01 | GSE67460 | GEO

Functional heterogeneity exceeds genetic heterogeneity in chronic myelomonocytic leukemia

Project description:Functional heterogeneity exceeds genetic heterogeneity in chronic myelomonocytic leukemia

| PRJNA464355 | ENA

Chronic myelomonocytic leukemia

Project description:Chronic myelomonocytic leukemia is an aggressive hematological malignancy with dismal outcomes, with the pCMML subtype in particular having median OS of <2 years and high rates of AML transformation (Patnaik et al., 2014). Given limited therapeutic options for affected patients, we carried out this study to define the genetic and epigenetic landscape of pCMML and identify therapies that could modify disease biology.

| EGAS00001005107 | EGA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data